Understanding the mechanism of insulin and insulin-like growth factor (IGF) receptor activation by IGF-II. 2011

Clair L Alvino, and Shee Chee Ong, and Kerrie A McNeil, and Carlie Delaine, and Grant W Booker, and John C Wallace, and Briony E Forbes
School of Molecular and Biomedical Science, The University of Adelaide, Adelaide, Australia.

BACKGROUND Insulin-like growth factor-II (IGF-II) promotes cell proliferation and survival and plays an important role in normal fetal development and placental function. IGF-II binds both the insulin-like growth factor receptor (IGF-1R) and insulin receptor isoform A (IR-A) with high affinity. Interestingly both IGF-II and the IR-A are often upregulated in cancer and IGF-II acts via both receptors to promote cancer proliferation. There is relatively little known about the mechanism of ligand induced activation of the insulin (IR) and IGF-1R. The recently solved IR structure reveals a folded over dimer with two potential ligand binding pockets arising from residues on each receptor half. Site-directed mutagenesis has mapped receptor residues important for ligand binding to two separate sites within the ligand binding pocket and we have recently shown that the IGFs have two separate binding surfaces which interact with the receptor sites 1 and 2. RESULTS In this study we describe a series of partial IGF-1R and IR agonists generated by mutating Glu12 of IGF-II. By comparing receptor binding affinities, abilities to induce negative cooperativity and potencies in receptor activation, we provide evidence that residue Glu12 bridges the two receptor halves leading to receptor activation. CONCLUSIONS This study provides novel insight into the mechanism of receptor binding and activation by IGF-II, which may be important for the future development of inhibitors of its action for the treatment of cancer.

UI MeSH Term Description Entries
D007334 Insulin-Like Growth Factor I A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor. IGF-I,Somatomedin C,IGF-1,IGF-I-SmC,Insulin Like Growth Factor I,Insulin-Like Somatomedin Peptide I,Insulin Like Somatomedin Peptide I
D007335 Insulin-Like Growth Factor II A well-characterized neutral peptide believed to be secreted by the LIVER and to circulate in the BLOOD. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on SOMATOTROPIN. It is believed to be a major fetal growth factor in contrast to INSULIN-LIKE GROWTH FACTOR I, which is a major growth factor in adults. IGF-II,Multiplication-Stimulating Activity,Somatomedin MSA,IGF-2,Insulin Like Growth Factor II,Insulin-Like Somatomedin Peptide II,Multiplication-Stimulating Factor,Somatomedin A,Factor, Multiplication-Stimulating,Insulin Like Somatomedin Peptide II,Multiplication Stimulating Activity,Multiplication Stimulating Factor
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011972 Receptor, Insulin A cell surface receptor for INSULIN. It comprises a tetramer of two alpha and two beta subunits which are derived from cleavage of a single precursor protein. The receptor contains an intrinsic TYROSINE KINASE domain that is located within the beta subunit. Activation of the receptor by INSULIN results in numerous metabolic changes including increased uptake of GLUCOSE into the liver, muscle, and ADIPOSE TISSUE. Insulin Receptor,Insulin Receptor Protein-Tyrosine Kinase,Insulin Receptor alpha Subunit,Insulin Receptor beta Subunit,Insulin Receptor alpha Chain,Insulin Receptor beta Chain,Insulin-Dependent Tyrosine Protein Kinase,Receptors, Insulin,Insulin Receptor Protein Tyrosine Kinase,Insulin Receptors
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001667 Binding, Competitive The interaction of two or more substrates or ligands with the same binding site. The displacement of one by the other is used in quantitative and selective affinity measurements. Competitive Binding

Related Publications

Clair L Alvino, and Shee Chee Ong, and Kerrie A McNeil, and Carlie Delaine, and Grant W Booker, and John C Wallace, and Briony E Forbes
July 1998, The international journal of biochemistry & cell biology,
Clair L Alvino, and Shee Chee Ong, and Kerrie A McNeil, and Carlie Delaine, and Grant W Booker, and John C Wallace, and Briony E Forbes
April 1997, Neurological research,
Clair L Alvino, and Shee Chee Ong, and Kerrie A McNeil, and Carlie Delaine, and Grant W Booker, and John C Wallace, and Briony E Forbes
July 2010, Nihon rinsho. Japanese journal of clinical medicine,
Clair L Alvino, and Shee Chee Ong, and Kerrie A McNeil, and Carlie Delaine, and Grant W Booker, and John C Wallace, and Briony E Forbes
August 2005, Nihon rinsho. Japanese journal of clinical medicine,
Clair L Alvino, and Shee Chee Ong, and Kerrie A McNeil, and Carlie Delaine, and Grant W Booker, and John C Wallace, and Briony E Forbes
May 2000, The Journal of biological chemistry,
Clair L Alvino, and Shee Chee Ong, and Kerrie A McNeil, and Carlie Delaine, and Grant W Booker, and John C Wallace, and Briony E Forbes
November 1992, Endocrinology,
Clair L Alvino, and Shee Chee Ong, and Kerrie A McNeil, and Carlie Delaine, and Grant W Booker, and John C Wallace, and Briony E Forbes
January 1994, Hormone research,
Clair L Alvino, and Shee Chee Ong, and Kerrie A McNeil, and Carlie Delaine, and Grant W Booker, and John C Wallace, and Briony E Forbes
October 1998, The Journal of biological chemistry,
Clair L Alvino, and Shee Chee Ong, and Kerrie A McNeil, and Carlie Delaine, and Grant W Booker, and John C Wallace, and Briony E Forbes
October 1990, Endocrinologia japonica,
Clair L Alvino, and Shee Chee Ong, and Kerrie A McNeil, and Carlie Delaine, and Grant W Booker, and John C Wallace, and Briony E Forbes
January 1995, Annales d'endocrinologie,
Copied contents to your clipboard!